
  
    
      
        
        By_IN next_JJ summer_NN ,_, more_JJR than_IN 40_CD %_NN of_IN 
        Streptococcus_NNP pneumoniae_NN strains_NNS in_IN the_DT United_NNP States_NNPS will_MD
        resist_VB both_DT penicillin_NN and_CC erythromycin_NN ,_, according_VBG to_TO a_DT recent_JJ prediction_NN from_IN the_DT Harvard_NNP
        School_NNP of_IN Public_NNP Health_NNP ._. The_DT forecast_NN ,_, based_VBN on_IN mathematical_JJ modeling_NN ,_, was_VBD published_VBN in_IN the_DT
        spring_NN of_IN 2003_CD ._. It_PRP 's_VBZ too_RB early_JJ to_TO tell_VB whether_IN that_DT prediction_NN is_VBZ precisely_RB on_IN track_NN ,_,
        according_VBG to_TO the_DT senior_JJ author_NN on_IN that_DT paper_NN ,_, Marc_NNP Lipsitch_NNP ._. But_CC no_DT one_CD doubts_NNS that_WDT
        multidrug_NN resistance_NN in_IN this_DT common_JJ bug—responsible_JJ for_IN diseases_NNS that_WDT range_NN from_IN sinus_JJ
        trouble_NN and_CC ear_NN infections_NNS to_TO meningitis_NNS and_CC pneumonia—is_NNS speeding_VBG up_RP ._.
        It_PRP is_VBZ the_DT certain_JJ fate_NN of_IN all_DT antibacterials_NNS to_TO be_VB fought_VBN off_RP eventually_RB by_IN the_DT
        pathogens_NNS they_PRP target_VBP ._. The_DT fact_NN that_IN the_DT process_NN is_VBZ accelerating_VBG has_VBZ been_VBN alarming_JJ public_JJ
        health_NN officials_NNS for_IN some_DT time_NN ,_, especially_RB in_IN the_DT United_NNP States_NNPS ._. We_PRP need_VBP new_JJ ways_NNS to_TO defeat_VB
        disease_NN ,_, and_CC we_PRP will_MD need_VB them_PRP forever_RB ._.
      
      
        Tried_NNP and_CC True—and_NNP Tired_NNP ?_.
        Antibiotics_NNP have_VBP traditionally_RB been_VBN plucked_VBN from_IN nature_NN 's_POS battleground_NN ._. For_IN billions_NNS of_IN
        years_NNS ,_, tiny_JJ organisms_NNS have_VBP engaged_VBN in_IN an_DT arms_NNS race_NN ,_, hurling_VBG toxic_JJ molecules_NNS at_IN each_DT other_JJ
        in_IN the_DT struggle_NN to_TO prosper_VB ._. Nearly_RB all_DT of_IN today_NN 's_POS antibiotics_NNS are_VBP versions_NNS of_IN weapons_NNS long_RB
        wielded_VBN by_IN microbes_NNS and_CC fungi_NNS ._. Chemical_NN synthesis_NN of_IN entirely_RB human-created_JJ antibiotics_NNS has_VBZ
        so_RB far_RB yielded_VBD only_RB fluoroquinolones_NNS ,_, a_DT group_NN of_IN broad-spectrum_JJ antibiotics_NNS that_WDT includes_VBZ
        Cipro_NNP ,_, which_WDT became_VBD famously_RB scarce_JJ during_IN the_DT 2001_CD anthrax_NN scare_NN ,_, and_CC linezolid_NN
        (_( trade-named_JJ Zyvox_NNP )_) ,_, which_WDT is_VBZ effective_JJ against_IN some_DT resistant_JJ strains_NNS of_IN 
        Staphylococcus_NNP ,_, 
        Streptococcus_NNP ,_, and_CC 
        Enterococcus_NNP ._.
        The_DT usual_JJ way_NN to_TO find_VB a_DT new_JJ antibiotic_NN has_VBZ been_VBN laborious_JJ screening_NN of_IN immense_JJ libraries_NNS
        of_IN compounds_NNS ,_, natural_JJ and_CC otherwise_RB ._. Some_DT argue_VBP that_DT screening_VBG chemical_NN libraries_NNS is_VBZ
        approaching_VBG a_DT deadend_NN ._. There_EX may_MD be_VB diminishing_VBG returns_NNS from_IN screening_NN ,_, but_CC it_PRP 's_VBZ not_RB quite_RB
        dead_JJ yet_RB :_: in_IN October_NNP ,_, researchers_NNS at_IN the_DT University_NNP of_IN Wisconsin_NNP at_IN Madison_NNP reported_VBD a_DT new_JJ
        class_NN of_IN bacterial_JJ RNA_NNP polymerase_NN inhibitors_NNS with_IN antibiotic_JJ potential_NN ._. They_PRP were_VBD found_VBN by_IN
        screening_VBG for_IN molecules_NNS that_DT prevent_VBP 
        Escherichia_NNP coli_NNS from_IN transcribing_VBG RNA_NNP ._.
        Christopher_NNP T_NN ._. Walsh_NNP of_IN Harvard_NNP Medical_NNP School_NNP says_VBZ screening_NN 's_POS problem_NN may_MD be_VB simply_RB
        that_IN libraries_NNS are_VBP n't_RB good_JJ enough_RB ._. Marine_NN organisms_NNS have_VBP not_RB been_VBN studied_VBN well_RB ,_, he_PRP points_VBZ
        out_IN ,_, and_CC 90_CD %_NN of_IN organisms_NNS in_IN the_DT biosphere_NN ca_MD n't_RB be_VB cultured_JJ in_IN standard_JJ ways_NNS ._. He_PRP says_VBZ ,_,
        “ We_PRP 're_VBP missing_VBG 90_CD %_NN of_IN them_PRP every_DT time_NN we_PRP go_VBP and_CC look_VB in_IN nature_NN ._.”
        Walsh_NNP is_VBZ doing_VBG his_PRP$ bit_NN to_TO create_VB new_JJ libraries_NNS ._. He_PRP and_CC his_PRP$ colleagues_NNS have_VBP recently_RB
        employed_VBN combinatorial_NN biosynthesis_NNS to_TO learn_VB how_WRB to_TO use_VB part_NN of_IN the_DT machinery_NN for_IN
        assembling_VBG cyclic_JJ peptide_NN antibiotics_NNS to_TO control_VB their_PRP$ architecture_NN ._. The_DT result_NN was_VBD a_DT small_JJ
        library_NN of_IN natural_JJ product_NN analogs_NNS ,_, some_DT of_IN which_WDT have_VBP improved_VBN antibiotic_JJ activity_NN against_IN
        common_JJ bacterial_JJ pathogens_NNS ._. “ There_EX are_VBP dozens_NNS of_IN such_JJ enzymatic_JJ domains_NNS that_IN in_IN principle_NN
        one_PRP could_MD clone_NN ,_, express_VB ,_, and_CC test_NN with_IN other_JJ substrates_NNS ._. I_PRP view_VBP that_IN as_IN the_DT kind_NN of_IN thing_NN
        we_PRP should_MD do_VB ,_,” he_PRP says_VBZ ._. For_IN example_NN ,_, Walsh_NNP suggests_VBZ ,_, it_PRP is_VBZ a_DT reasonable_JJ approach_NN to_TO
        second-generation_JJ improvement_NN of_IN daptomycin_NN ,_, the_DT antibiotic_JJ most_RBS recently_RB approved_VBD for_IN sale_NN
        in_IN the_DT United_NNP States_NNPS ._.
      
      
        Improving_NN on_IN Nature_NNP
        Walsh_NNP collaborates_NNS with_IN Chaitan_NNP Khosla_NNP of_IN Stanford_NNP University_NNP on_IN finding_VBG ways_NNS to_TO make_VB
        existing_VBG antibiotics_NNS better_JJR ._. They_PRP are_VBP studying_VBG biosynthesis_NNS of_IN rifamycin_NN ,_, an_DT antibiotic_NN
        that_WDT is_VBZ increasingly_RB less_RBR effective_JJ against_IN its_PRP$ prime_JJ target_NN ,_, tuberculosis_NNS (_( TB_NN )_) (_( see_VB Figure_NN
        1_LS )_) ._. “ In_IN the_DT course_NN of_IN learning_VBG about_IN that_DT pathway_NN ,_, we_PRP 've_VBP learned_VBN a_DT few_JJ interesting_JJ things_NNS
        lately_RB about_IN how_WRB that_DT molecule_NN is_VBZ initiated_VBN ,_, and_CC we_PRP 're_VBP trying_VBG to_TO apply_VB it_PRP in_IN other_JJ
        contexts_NNS ,_, especially_RB in_IN the_DT context_NN of_IN erythromycin_NN biosynthesis_NNS ,_,” Khosla_NNP says_VBZ ._. The_DT idea_NN
        would_MD be_VB to_TO make_VB a_DT molecule_NN that_WDT might_MD be_VB more_RBR effective_JJ against_IN bacteria_NNS that_WDT are_VBP becoming_VBG
        resistant_JJ to_TO rifamycin—and_NN are_VBP already_RB naturally_RB resistant_JJ to_TO molecules_NNS like_IN
        erythromycin_NN ._.
        “ Basically_RB ,_, what_WP we_PRP do_VBP is_VBZ to_TO try_VB and_CC figure_VB out_IN new_JJ ways_NNS to_TO hijack_NN the_DT biosynthesis_NNS of_IN
        antibiotics_NNS in_IN nature_NN so_RB as_IN to_TO modify_VB their_PRP$ structures_NNS with_IN the_DT goal_NN of_IN improving_VBG them_PRP ,_,”
        Khosla_NNP explains_VBZ ._. He_PRP works_VBZ with_IN an_DT important_JJ class_NN of_IN natural_JJ antibiotics_NNS called_VBD polyketides_NNS
        that_WDT have_VBP generated_VBN dozens_NNS of_IN drugs_NNS ,_, including_VBG erythromycin_NN ._.
        Polyketides_NNP are_VBP secondary_JJ metabolites_NNS (_( which_WDT give_VBP their_PRP$ producers_NNS a_DT competitive_JJ
        advantage_NN in_IN their_PRP$ environment_NN )_) produced_VBN mostly_RB by_IN bacteria_NNS and_CC fungi_NNS and_CC made_VBN by_IN a_DT complex_JJ
        and_CC structurally_RB diverse_JJ family_NN of_IN enzymes_NNS called_VBD polyketide_NN synthases_NNS (_( see_VB the_DT primer_NN by_IN
        David_NNP Hopwood_NNP in_IN this_DT issue_NN of_IN 
        PLoS_NNP Biology_NNP )_) ._. Among_IN them_PRP are_VBP the_DT anthracyclines_NNS ,_, a_DT group_NN of_IN anticancer_NN
        drugs_NNS and_CC antibacterials_NNS that_WDT includes_VBZ tetracycline_NN ._. In_IN this_DT issue_NN of_IN 
        PloS_NNP Biology_NNP ,_, Khosla_NNP and_CC his_PRP$ colleagues_NNS report_VBP that_IN they_PRP can_MD make_VB
        selective_JJ positional_JJ modifications_NNS in_IN existing_VBG anthracycline_NN antibiotics_NNS by_IN starting_VBG in_IN a_DT
        different_JJ way_NN with_IN a_DT different_JJ starting_NN molecule_NN ._. The_DT molecule_NN came_VBD from_IN a_DT natural_JJ
        anthracycline_NN antibiotic_JJ ,_, an_DT estrogen_NN receptor_NN antagonist_NN called_VBD R_NN 1128_CD ._. R_NN 1128_CD is_VBZ made_VBN via_IN
        two_CD modules_NNS of_IN enzymes_NNS that_WDT work_NN sequentially_RB ;_: the_DT first_JJ module_NN starts_VBZ the_DT process_NN ,_, and_CC the_DT
        second_JJ completes_VBZ it_PRP ._. This_DT division_NN of_IN labor_NN permitted_VBD the_DT researchers_NNS to_TO tack_NN the_DT first_JJ
        R_NN 1128_CD module_NN onto_IN two_CD other_JJ enzyme_NN systems_NNS ,_, thus_RB engineering_NN completely_RB new_JJ anthracyclines_NNS ._.
        Some_DT were_VBD more_RBR active_JJ in_IN two_CD types_NNS of_IN assays_NNS than_IN the_DT natural_JJ parent_NN molecule_NN ._. “ One_CD setting_VBG
        was_VBD an_DT assay_NN on_IN an_DT estrogen-sensitive_JJ cancer_NN cell_NN line_NN ._. Another_DT setting_VBG was_VBD an_DT assay_NN to_TO
        probe_VB activity_NN of_IN an_DT enzyme_NN that_WDT 's_VBZ of_IN particular_JJ interest_NN in_IN Type_NNP 2_CD diabetes_NN ,_, called_VBN
        glucose-_NN 6_CD -_: phosphate_NN translocase_NN ._.” The_DT work_NN also_RB revealed_VBD fundamental_JJ mechanistic_JJ features_NNS
        of_IN the_DT polyketide_NN synthases_NNS ,_, Khosla_NNP says_VBZ ._.
        The_DT researchers_NNS did_VBD n't_RB study_VB the_DT new_JJ anthracyclines_NNS '_POS effects_NNS on_IN bacteria_NNS ,_, but_CC Khosla_NNP
        notes_NNS that_IN the_DT general_JJ principle_NN should_MD apply_VB to_TO other_JJ classes_NNS of_IN compounds_NNS ,_, although_IN the_DT
        details_NNS of_IN how_WRB it_PRP 's_VBZ implemented_VBN will_MD vary_VB from_IN system_NN to_TO system_NN ._. He_PRP says_VBZ ,_, “ The_DT upshot_NN of_IN
        this_DT paper_NN is_VBZ that_IN it_PRP is_VBZ now_RB possible_JJ to_TO modify_VB a_DT particular_JJ methyl_NN group_NN in_IN just_RB about_IN any_DT
        anthracycline_NN antibiotic_JJ ._.”
      
      
        Finding_VBG New_NNP Targets_NNP
        Instead_RB of_IN searching_VBG for_IN new_JJ antibiotics_NNS by_IN modifying_VBG existing_VBG ones_NNS ,_, some_DT researchers_NNS
        are_VBP trying_VBG something_NN completely_RB different—first_NN finding_VBG the_DT most_RBS vulnerable_JJ targets_NNS in_IN a_DT
        bacterium_NN and_CC then_RB designing_VBG something_NN that_IN hits_NNS one_CD or_CC more_JJR of_IN them_PRP hard_JJ ._. “ You_PRP have_VBP to_TO
        understand_VB a_DT helluva_NN lot_NN more_JJR about_IN how_WRB these_DT little_JJ cells_NNS work_VBP ._. In_IN fact_NN ,_, we_PRP think_VBP we_PRP
        understand_VBP a_DT lot_NN ,_, but_CC I_PRP think_VBP we_PRP can_MD understand_VB almost_RB everything_NN now_RB that_IN we_PRP have_VBP all_PDT the_DT
        genomes_NNS ,_,” says_VBZ Lucy_NNP Shapiro_NNP of_IN Stanford_NNP University_NNP School_NNP of_IN Medicine_NNP ._. While_IN having_VBG full_JJ
        genome_NN sequences—more_NN than_IN 100_CD microbe_NN sequences_NNS have_VBP been_VBN completed—is_NNS essential_JJ ,_, Shapiro_NNP
        believes_VBZ that_IN knocking_VBG outs_NNS genes_NNS galore_NN to_TO find_VB out_IN which_WDT ones_NNS are_VBP necessary_JJ and_CC going_VBG
        after_IN them_PRP all_DT is_VBZ not_RB a_DT sensible_JJ strategy_NN ._. She_PRP observes_VBZ ,_, “ People_NNS have_VBP been_VBN doing_VBG that_IN for_IN a_DT
        while_NN with_IN absolutely_RB no_DT success_NN ._. That_DT 's_VBZ really_RB going_VBG after_IN the_DT problem_NN with_IN a_DT Howitzer_NNP
        instead_RB of_IN with_IN an_DT intelligent_JJ approach_NN ._.”
        So_RB instead_RB of_IN screening_NN libraries_NNS of_IN existing_VBG compounds_NNS ,_, Shapiro_NNP prefers_VBZ using_VBG
        structural_JJ information_NN about_IN drug_NN targets_NNS or_CC their_PRP$ natural_JJ ligands_NNS to_TO create_VB new_JJ drugs_NNS ,_, an_DT
        approach_NN known_VBN as_IN rational_JJ drug_NN design_NN ._. And_CC instead_RB of_IN looking_VBG at_IN all_DT essential_JJ genes_NNS in_IN a_DT
        bacterium_NN and_CC choosing_VBG one_CD to_TO target_VB ,_, she_PRP and_CC her_PRP$ colleagues_NNS look_VBP at_IN genetic_JJ circuitry_NN that_IN
        controls_VBZ the_DT cell_NN cycle_NN ,_, the_DT pathway_NN that_WDT coordinates_VBZ cell_NN growth_NN and_CC differentiation_NN ._. They_PRP
        have_VBP identified_VBN key_JJ control_NN points_NNS ,_, or_CC nodes_NNS ,_, in_IN the_DT circuitry_NN for_IN their_PRP$ favorite_JJ study_NN
        subject_JJ ,_, 
        Caulobacter_NNP crescentus_JJ ._. Thus_RB ,_, they_PRP have_VBP found_VBN critical_JJ genes_NNS
        encoding_VBG proteins_NNS that_WDT control_NN several_JJ critical_JJ functions_NNS in_IN the_DT cell_NN ._. Their_PRP$ first_JJ
        candidate_NN was_VBD an_DT essential_JJ enzyme_NN ,_, a_DT methyltransferase_NN called_VBN CcrM_NNP ,_, that_WDT prevents_VBZ a_DT
        particular_JJ piece_NN of_IN DNA_NNP from_IN being_VBG expressed_VBN in_IN a_DT cell_NN by_IN tagging_VBG it_PRP with_IN a_DT methyl_NN
        group_NN ._.
        Antibiotic_NNP discovery_NN is_VBZ all_DT chemistry_NN ,_, Shapiro_NNP says_VBZ ,_, which_WDT is_VBZ why_WRB she_PRP joined_VBD with_IN
        biochemist_NN Stephen_NNP J_NNP ._. Benkovic_NNP of_IN Pennsylvania_NNP State_NNP University_NNP ._. They_PRP did_VBD n't_RB know_VB the_DT
        structure_NN of_IN CcrM_NNP ,_, Benkovic_NNP explains_VBZ ,_, but_CC the_DT literature_NN about_IN other_JJ methyltransferases_NNS
        suggested_VBD that_IN the_DT adenine_NN molecule_NN ,_, which_WDT is_VBZ the_DT substrate_NN for_IN CcrM_NNP within_IN DNA_NNP ,_, binds_NNS to_TO a_DT
        specific_JJ region_NN of_IN the_DT enzyme_NN ._.
        The_DT researchers_NNS designed_VBD adenine-like_JJ molecules_NNS that_WDT would_MD bind_NN to_TO CcrM_NNP and_CC then_RB
        developed_VBN inhibitors_NNS ._. Benkovic_NNP says_VBZ ,_, “ We_PRP already_RB knew_VBD what_WP kind_NN of_IN structure_NN we_PRP wanted_VBD ,_, and_CC
        we_PRP simply_RB fine-tuned_JJ it_PRP ._.” They_PRP worked_VBD their_PRP$ way_NN through_IN 1_CD ,_, 000_CD inhibitor_NN candidates_NNS ,_, ending_VBG
        up_RP with_IN a_DT small_JJ subset—no_NN more_JJR than_IN about_IN 20_CD —_NN that_IN not_RB only_RB inhibited_VBD CcrM_NNP ,_, but_CC also_RB killed_VBN 
        Caulobacter_NNP very_RB quickly_RB ._.
        And_CC not_RB only_RB inoffensive_JJ 
        Caulobacter_NNP ._. The_DT compounds_NNS knock_NN out_IN other_JJ gram-negative_JJ
        bacteria_NNS ,_, such_JJ as_IN the_DT pathogens_NNS 
        Brucella_NNP abortus_JJ and_CC 
        Francisella_NNP tularensis_NNS ._. Some_DT even_RB killed_VBN off_IN anthrax_NN ,_, a_DT big_JJ
        surprise_NN because_IN it_PRP is_VBZ gram-positive_JJ and_CC so_RB has_VBZ much_RB thicker_JJR cell_NN walls_NNS than_IN gram-negative_JJ
        bacteria_NNS ._. The_DT researchers_NNS undertook_VBD an_DT exhaustive_JJ series_NN of_IN experiments_NNS to_TO identify_VB which_WDT
        gram-positive_JJ bacteria_NNS would_MD be_VB affected_VBN by_IN which_WDT compounds_NNS ._. The_DT list_NN of_IN sensitive_JJ
        pathogens_NNS now_RB includes_VBZ multidrug-resistant_JJ 
        Streptococcus_NNP ,_, 
        Staphylococcus_NNP ,_, and_CC 
        Mycobacterium_NNP tuberculosis_NNS ._.
        More_RBR recently_RB ,_, Shapiro_NNP reports_NNS ,_, they_PRP have_VBP demonstrated_VBN efficacy_NN against_IN rats_NNS infected_VBN
        with_IN anthrax_NN or_CC multidrug-resistant_JJ 
        Staph_NNP ,_, although_IN the_DT compounds_NNS save_VBP only_RB about_IN 60_CD %_NN of_IN the_DT rats_NNS
        at_IN present_NN ._. She_PRP notes_VBZ ,_, “ So_IN we_PRP have_VBP a_DT long_JJ way_NN to_TO go_VB ._. But_CC this_DT has_VBZ proven_VBN that_IN if_IN you_PRP go_VBP
        after_IN something_NN using_VBG some_DT rational_JJ approach_NN instead_RB of_IN hit-and-miss_JJ ,_, you_PRP 'll_MD probably_RB have_VB
        more_JJR success_NN than_IN by_IN the_DT other_JJ method_NN ._.”
        Benkovic_NNP points_NNS out_RP that_IN theirs_PRP is_VBZ an_DT entirely_RB new_JJ class_NN of_IN compounds_NNS ,_, small_JJ molecular_JJ
        weight_NN compounds_NNS that_WDT can_MD be_VB made_VBN in_IN a_DT few_JJ steps_NNS ._. He_PRP says_VBZ ,_, “ They_PRP do_VBP n't_RB look_VB like_IN the_DT normal_JJ
        antibiotic_NN ,_, so_IN that_DT 's_VBZ why_WRB I_PRP think_VBP they_PRP 're_VBP fairly_RB unique_JJ ._.” The_DT basic_JJ research_NN was_VBD done_VBN under_IN
        a_DT grant_NN from_IN the_DT Defense_NNP Advanced_NNP Research_NNP Projects_NNPS Agency_NNP (_( DARPA_NNP )_) ,_, the_DT United_NNP States_NNP
        Department_NNP of_IN Defense_NNP 's_POS (_( DOD_NNP )_) central_JJ research_NN and_CC development_NN organization_NN ,_, and_CC once_RB the_DT
        researchers_NNS realized_VBD they_PRP wanted_VBD to_TO develop_VB drugs_NNS against_IN three_CD agents_NNS that_WDT have_VBP been_VBN
        considered_VBN bioterrorism_NN threats_NNS —_NN 
        Brucella_NNP ,_, tularensis_NNS ,_, and_CC anthrax_NN —_NN they_PRP established_VBD a_DT separate_JJ
        operation_NN ,_, Anacor_NNP Pharmaceuticals_NNP ,_, which_WDT is_VBZ developing_VBG them_PRP with_IN DOD_NNP funding_NN and_CC without_IN
        Shapiro_NNP ._. In_IN her_PRP$ Stanford_NNP lab_NN ,_, she_PRP continues_VBZ her_PRP$ fundamental_JJ research_NN to_TO define_VB the_DT complete_JJ
        genetic_JJ circuitry_NN of_IN 
        Caulobacter_NNP ,_, hoping_VBG to_TO identify_VB additional_JJ nodes_NNS in_IN the_DT
        circuit_NN ._. She_PRP says_VBZ ,_, “ I_PRP am_VBP not_RB doing_VBG it_PRP to_TO develop_VB antibiotics_NNS ;_: that_DT 's_VBZ what_WP comes_VBZ out_IN of_IN the_DT
        work_NN ._. My_PRP$ goal_NN is_VBZ to_TO understand_VB how_WRB the_DT cell_NN works_NNS ._. I_PRP think_VBP a_DT lot_NN of_IN studies_NNS in_IN pathogenesis_NNS
        should_MD not_RB be_VB just_RB to_TO understand_VB pathogenic_JJ organisms_NNS ,_, but_CC to_TO understand_VB the_DT complete_JJ
        network_NN of_IN regulatory_JJ mechanisms_NNS that_IN controls_VBZ the_DT bacterial_JJ cell_NN ._.”
      
      
        Phage_NNP Therapy_NNP
        The_DT most_RBS radical_JJ approach_NN to_TO new_JJ antibiotics_NNS may_MD be_VB the_DT resurrection_NN of_IN an_DT old_JJ idea_NN :_:
        bacteriophage_NN therapy_NN (_( see_VB Figure_NN 2_LS )_) ._. Late_RB in_IN the_DT 19_CD th_NN century_NN ,_, a_DT researcher_NN noticed_VBD that_DT
        water_NN from_IN some_DT of_IN India_NNP 's_POS sacred_JJ rivers_NNS combated_JJ cholera_NN ._. Some_DT years_NNS later_RB ,_, the_DT active_JJ
        agents_NNS were_VBD identified_VBN as_IN viruses_NNS that_IN infected_JJ bacteria_NNS ._. Such_JJ viruses_NNS are_VBP called_VBN
        bacteriophage_NN ,_, or_CC phage_NN for_IN short_JJ ._. There_EX were_VBD reports_NNS of_IN phage_NN success_NN against_IN dysentery_NN ,_,
        typhoid_NN ,_, and_CC plague_VB ,_, and_CC bacteriophage_NN therapy_NN had_VBD a_DT brief_JJ heyday_NN ,_, especially_RB in_IN the_DT 1920_CD s_VBZ ._.
        Results_NNS on_IN other_JJ diseases_NNS were_VBD mixed_JJ ,_, and_CC with_IN the_DT appearance_NN of_IN antibiotics_NNS ,_, phage_NN therapy_NN
        became_VBD unfashionable_JJ in_IN the_DT United_NNP States_NNPS ,_, although_IN it_PRP has_VBZ continued_VBN in_IN Russia_NNP and_CC Eastern_NNP
        Europe_NNP ._.
        Phage_NNP were_VBD the_DT model_NN organisms_NNS of_IN choice_NN for_IN genetics_NNS research_NN in_IN the_DT 1930_CD s_VBZ and_CC 1940_CD s_VBZ ,_,
        but_CC became_VBD less_RBR fashionable_JJ as_IN research_NN tools_NNS when_WRB investigators_NNS moved_VBD on_IN to_TO eukaryotes_NNS ._. A_DT
        few_JJ held_VBN on_IN ,_, like_IN Ry_NNP Young_NNP of_IN Texas_NNP A_DT &_CC M_NNP University_NNP ,_, who_WP has_VBZ made_VBN phage-induced_JJ cell_NN
        lysis_NNS his_PRP$ life_NN 's_POS work_NN ._. “ The_DT cell_NN is_VBZ basically_RB genetically_RB dead_JJ as_IN soon_RB as_IN the_DT phage_NN goes_VBZ in_IN
        there_RB ,_, but_CC it_PRP will_MD keep_VB living_VBG as_IN sort_NN of_IN an_DT infected_JJ zombie_NN for_IN as_RB long_RB as_IN the_DT phage_NN wants_VBZ
        it_PRP to_TO ,_, with_IN virus_NN particles_NNS accumulating_VBG inside_IN the_DT cell_NN ,_,” he_PRP explains_VBZ ._. “ Only_RB when_WRB the_DT
        phage_NN is_VBZ ready_JJ and_CC has_VBZ decided_VBN that_IN it_PRP 's_VBZ the_DT right_JJ time_NN will_MD it_PRP pull_VB the_DT trigger_NN ._. And_CC the_DT
        cell_NN blows_NNS up_RB ._.” The_DT freed_VBN phage_NN then_RB spew_NN forth_RB to_TO infect_NN new_JJ cells_NNS ._.
        Antibiotic_NNP resistance_NN has_VBZ led_VBN to_TO new_JJ interest_NN in_IN phage_NN therapy_NN by_IN several_JJ small_JJ biotech_JJ
        companies_NNS ._. Young_NNP continues_VBZ basic_JJ research_NN at_IN Texas_NNP A_DT &_CC M_NNP ,_, but_CC has_VBZ also_RB joined_VBN one_CD of_IN
        them_PRP ,_, GangaGen_NNP ,_, providing_VBG bacteriophage_NN expertise_NN to_TO its_PRP$ labs_NNS ._.
        Phage_NNP do_VBP kill_VB pathogenic_JJ bacteria_NNS effectively_RB ,_, and_CC they_PRP do_VBP it_PRP without_IN penetrating_VBG human_JJ
        cells_NNS ,_, which_WDT they_PRP ca_MD n't_RB even_RB recognize_VB ._. So_RB what_WP is_VBZ keeping_VBG phage_NN therapy_NN out_IN of_IN the_DT clinic_NN ?_.
        Problems_NNP that_IN some_DT doubt_NN can_MD be_VB overcome_VBN ._.
        Because_IN bacteria_NNS develop_VBP resistance_NN to_TO phage_NN rapidly_RB ,_, phage_NN therapy_NN companies_NNS will_MD need_VB
        to_TO direct_JJ cocktails_NNS against_IN a_DT single_JJ pathogen_NN ,_, according_VBG to_TO Vincent_NNP Fischetti_NNP at_IN The_DT
        Rockefeller_NNP University_NNP ._. Phage_NNP are_VBP also_RB antigenic_JJ ,_, and_CC the_DT antibodies_NNS they_PRP stimulate_VB will_MD
        neutralize_NN their_PRP$ effects_NNS during_IN subsequent_JJ treatment_NN ,_, he_PRP says_VBZ ._. But_CC the_DT chief_JJ problem_NN
        appears_VBZ to_TO be_VB regulatory—regulatory_NN in_IN the_DT political_JJ ,_, rather_RB than_IN the_DT genetic_JJ ,_, sense_NN ._. When_WRB
        bacteriophage_NN package_NN their_PRP$ DNA_NNP ,_, they_PRP occasionally_RB include_VBP varying_VBG amounts_NNS of_IN their_PRP$ hosts_NNS '_POS
        DNA_NNP ,_, too_RB ._. This_DT miscellany_NN ,_, Fischetti_NNP points_NNS out_IN ,_, is_VBZ likely_JJ to_TO make_VB the_DT Food_NNP and_CC Drug_NNP
        Administration_NNP unhappy_JJ ._. “ Phage_NNP normally_RB are_VBP very_RB fragile_JJ ,_, their_PRP$ tails_NNS break_VBP ,_, so_RB lot-to-lot_JJ
        homogeneity_NN could_MD be_VB a_DT problem_NN too_RB ,_,” he_PRP adds_VBZ ._. “ So_RB even_RB though_IN it_PRP will_MD work_VB ,_, I_PRP think_VBP they_PRP 'll_MD
        have_VB an_DT uphill_JJ battle_NN ._.” Phage_NNP may_MD well_RB enter_VB agricultural_JJ or_CC veterinary_JJ use_NN ,_, he_PRP predicts_VBZ ,_,
        but_CC are_VBP probably_RB not_RB going_VBG to_TO be_VB available_JJ to_TO patients_NNS in_IN the_DT United_NNP States_NNPS any_DT time_NN
        soon_RB ._.
        Fischetti_NNP chose_VBD a_DT different_JJ approach_NN to_TO phage_NN therapy_NN ._. It_PRP does_VBZ not_RB rely_VB on_IN phage_NN
        themselves_PRP ,_, but_CC on_IN enzymes_NNS that_WDT phage_NN produce_NN to_TO smash_VB their_PRP$ way_NN out_IN of_IN their_PRP$ host_NN bacteria_NNS
        so_IN they_PRP can_MD infect_NN new_JJ hosts_NNS ._. He_PRP and_CC his_PRP$ colleagues_NNS employ_VBP these_DT enzymes_NNS externally_RB to_TO kill_VB
        bacteria_NNS ._. He_PRP reports_VBZ ,_, “ We_PRP now_RB have_VBP enzymes_NNS that_DT will_MD kill_VB 
        Strep_NNP pyogenes_NNS ,_, pneumococci_NN ,_, 
        Strep_NNP pneumoniae_NN ,_, 
        Bacillus_NN anthracis_NNS ,_, 
        Enterococcus_NNP faecalis_NNS ,_, and_CC group_NN B_NNP 
        Strep_NNP ._. The_DT beauty_NN of_IN these_DT enzymes_NNS is_VBZ that_IN they_PRP are_VBP targeted_VBN
        killing_VBG ._. You_PRP only_RB kill_VBP the_DT organism_NN you_PRP intend_VBP to_TO kill_VB ,_, without_IN destroying_VBG or_CC affecting_VBG the_DT
        surrounding_VBG organisms_NNS that_WDT are_VBP necessary_JJ for_IN health_NN ._.”
        The_DT enzymes_NNS can_MD be_VB loaded_VBN into_IN a_DT nasal_NN spray_NN that_IN wipes_NNS out_RP pathogens_NNS such_JJ as_IN 
        Pneumococcus_NNP ,_, 
        Staphylococcus_NNP ,_, and_CC group_VB A_DT 
        Strep_NNP on_IN contact_NN with_IN mucous_JJ membranes_NNS ._. The_DT strategy_NN might_MD
        prevent_VB bacterial_JJ infections_NNS from_IN spreading_VBG in_IN close_JJ quarters_NNS like_IN hospitals_NNS ,_, nursing_NN
        homes_NNS ,_, and_CC daycare_NN centers_NNS ._. Fischetti_NNP says_VBZ ,_, “ Clinical_NNP trials_NNS would_MD tell_VB us_PRP how_WRB often_RB we_PRP had_VBD
        to_TO treat_VB ,_, but_CC more_RBR important_JJ ,_, we_PRP 'd_MD have_VB a_DT reagent_NN that_WDT could_MD treat_VB people_NNS who_WP walk_VBP out_RP the_DT
        door_NN of_IN the_DT hospital_NN to_TO eliminate_VB or_CC reduce_VB the_DT transmission_NN of_IN resistant_JJ organisms_NNS into_IN
        the_DT community_NN ._. We_PRP do_VBP n't_RB have_VB that_DT capability_NN right_RB now_RB ._.”
        Fischetti_NNP and_CC his_PRP$ colleagues_NNS have_VBP moved_VBN on_IN to_TO using_VBG the_DT enzymes_NNS systemically_RB to_TO wipe_VB out_IN
        
        Bacillus_NN anthracis_NNS spores_NNS ,_, preventing_VBG them_PRP from_IN germinating_VBG and_CC
        seething_VBG through_IN the_DT bloodstream_NN ,_, producing_VBG deadly_JJ toxins_NNS ._. An_DT IV_NNP drip_NN would_MD be_VB started_VBN
        after_IN exposure_NN to_TO the_DT spores_NNS ._. The_DT method_NN ,_, Fischetti_NNP reports_NNS ,_, is_VBZ already_RB successful_JJ in_IN mice_NNS ;_:
        clinical_JJ trials_NNS will_MD determine_VB how_WRB long_JJ treatment_NN must_MD be_VB continued_VBN ,_, perhaps_RB a_DT week_NN or_CC so_RB ._.
        They_PRP have_VBP also_RB eliminated_VBN septicemia_NN from_IN pneumocci_NN with_IN the_DT same_JJ intravenous_JJ method_NN ._.
        Up_IN to_TO now_RB the_DT enzymes_NNS must_MD make_VB contact_NN with_IN bacteria_NNS to_TO kill_VB ,_, but_CC Fischetti_NNP is_VBZ hoping_VBG
        that_IN a_DT new_JJ generation_NN of_IN engineered_VBN enzymes_NNS will_MD be_VB able_JJ to_TO kill_VB pathogens_NNS inside_IN cells_NNS
        too_RB ._. A_DT second_JJ disadvantage_NN is_VBZ that_IN they_PRP are_VBP effective_JJ only_RB against_IN gram-positive_JJ bacteria_NNS ,_,
        although_IN that_DT group_NN includes_VBZ many_JJ vicious_JJ pathogens_NNS ._.
        But_CC phage_NN enzymes_NNS seem_VBP to_TO offer_VB one_CD very_RB big_JJ advantage_NN :_: resistance_NN to_TO them_PRP has_VBZ yet_RB to_TO
        develop_VB ._. Fischetti_NNP says_VBZ ,_, “ We_PRP 've_VBP tried_VBN very_RB hard_JJ to_TO identify_VB resistant_JJ bacteria_NNS ,_, but_CC so_RB far_RB
        we_PRP have_VBP n't_RB found_VBN resistant_JJ organisms_NNS in_IN all_DT three_CD of_IN the_DT enzymes_NNS we_PRP 're_VBP working_VBG with_IN ._. It_PRP
        appears_VBZ to_TO be_VB a_DT very_RB rare_JJ event_NN ,_, much_JJ rarer_NN than_IN resistance_NN to_TO antibiotics_NNS ._.” Fischetti_NNP
        cautions_VBZ against_IN expecting_VBG that_DT gladsome_NN state_NN to_TO last_VB forever_RB ,_, but_CC he_PRP points_VBZ out_RP that_IN even_RB
        if_IN widespread_JJ resistance_NN takes_VBZ the_DT same_JJ 40_CD or_CC 50_CD years_NNS that_IN antibiotics_NNS required_VBN to_TO become_VB
        significantly_RB resistant_JJ ,_, phage_NN enzymes_NNS could_MD buy_VB researchers_NNS decades_NNS for_IN inventing_VBG other_JJ
        approaches_NNS ._.
      
      
        Antibiotics_NNP in_IN the_DT 21_CD st_NN Century_NNP
        There_EX is_VBZ no_DT shortage_NN of_IN ideas_NNS for_IN unearthing_VBG new_JJ antibiotic_JJ candidates_NNS ._. Why_WRB are_VBP they_PRP so_RB
        slow_JJ to_TO enter_VB medical_JJ practice_NN ?_. The_DT bottleneck_NN ,_, researchers_NNS agree_VBP ,_, lies_VBZ in_IN the_DT development_NN
        process_NN of_IN turning_VBG them_PRP into_IN effective_JJ therapies_NNS ._. Several_JJ researchers_NNS blame_VBP the_DT big_JJ
        pharmaceutical_JJ companies_NNS that_WDT got_VBD so_RB big_JJ by_IN leading_VBG the_DT way_NN to_TO new_JJ drugs_NNS for_IN battling_VBG
        infectious_JJ disease_NN ,_, but_CC in_IN recent_JJ years_NNS have_VBP dropped_VBN out_RP ._. Fischetti_NNP complains_VBZ ,_, “ These_DT are_VBP
        the_DT big_JJ companies_NNS that_WDT have_VBP the_DT money_NN to_TO develop_VB antiinfectives_NNS ,_, but_CC they_PRP leave_VBP it_PRP to_TO small_JJ
        biotech_JJ companies_NNS ,_, and_CC it_PRP 's_VBZ not_RB going_VBG to_TO happen_VB as_RB rapidly_RB as_IN it_PRP should_MD ._. I_PRP think_VBP it_PRP 's_VBZ
        really_RB unconscionable_JJ for_IN these_DT big_JJ companies_NNS to_TO drop_VB the_DT ball_NN because_IN it_PRP 's_VBZ not_RB going_VBG to_TO be_VB
        a_DT billion-dollar_JJ market_NN for_IN them_PRP and_CC that_DT 's_VBZ what_WP they_PRP 're_VBP looking_VBG for_IN ._.”
        Half_PDT a_DT billion_CD at_IN least_JJS ,_, says_VBZ Francis_NNP Tally_NNP ,_, a_DT big_JJ pharmaceuticals_NNS veteran_NN who_WP is_VBZ now_RB
        chief_JJ scientific_JJ officer_NN at_IN Cubist_NNP Pharmaceuticals_NNP ,_, a_DT biotech_JJ company_NN located_VBN in_IN Lexington_NNP ,_,
        Massachusetts_NNP ._. According_VBG to_TO Tally_NNP ,_, Cubist_NNP produced_VBD daptomycin_NN ,_, approved_VBN in_IN September_NNP 2003_CD ,_,
        by_IN licensing_VBG it_PRP from_IN Eli_NNP Lilly_NNP ,_, which_WDT shelved_VBD the_DT new_JJ compound_NN after_IN concluding_VBG its_PRP$
        potential_JJ market_NN was_VBD only_RB $_$ 250_CD million_CD ._.
        But_CC ,_, Tally_NNP argues_VBZ ,_, the_DT size_NN of_IN the_DT market_NN is_VBZ not_RB the_DT only_JJ barrier_NN to_TO new_JJ antibiotics_NNS ._.
        Combinatorial_NNP chemistry_NN and_CC the_DT genomics_NNS revolution_NN have_VBP simply_RB not_RB delivered_VBN on_IN their_PRP$
        early_JJ promise_NN ._. “ The_DT pipeline_NN is_VBZ very_RB dry_JJ ,_,” he_PRP says_VBZ ._. “ There_EX 's_VBZ been_VBN a_DT real_JJ lag_NN at_IN the_DT basic_JJ
        research_NN level_NN ._.”
        “ Antibiotic_NNP discovery_NN is_VBZ hard_JJ ,_,” Shapiro_NNP says_VBZ ._. “ It_PRP 's_VBZ a_DT huge_JJ long_JJ process_NN to_TO get_VB a_DT decent_JJ
        antibiotic_NN ._.” Walsh_NNP agrees_VBZ ._. “ It_PRP 's_VBZ easier_JJR to_TO find_VB inhibitors_NNS of_IN particular_JJ enzymes_NNS for_IN
        particular_JJ processes—and_NN a_DT very_RB long_JJ road_NN to_TO convert_VB that_IN into_IN something_NN for_IN
        development_NN ._.”
        In_IN the_DT meantime_NN ,_, there_EX is_VBZ a_DT rising_VBG clamor_NN to_TO slow_VB down_RP the_DT rate_NN at_IN which_WDT bacteria_NNS
        develop_VBP resistance_NN ._. Doctors_NNS are_VBP exhorted_JJ to_TO cut_VB back_RB on_IN prescribing_VBG antibiotics_NNS and_CC decline_NN
        to_TO prescribe_VB for_IN viral_JJ diseases_NNS ,_, which_WDT antibiotics_NNS ca_MD n't_RB combat_VB ,_, even_RB when_WRB their_PRP$ patients_NNS
        badger_NN them_PRP ._.
        But_CC even_RB if_IN antibiotic_JJ consumption_NN slowed_VBD ,_, we_PRP will_MD still_RB need_VB new_JJ antibiotics_NNS ._. “ I_PRP always_RB
        say_VBP it_PRP 's_VBZ not_RB a_DT matter_NN of_IN if_IN ,_, it_PRP 's_VBZ only_RB a_DT matter_NN of_IN when_WRB ,_,” says_VBZ Walsh_NNP ._. “ There_EX will_MD always_RB be_VB
        a_DT need_NN for_IN new_JJ antibiotics_NNS because_IN the_DT clock_NN starts_VBZ ticking_VBG on_IN the_DT useful_JJ lifetime_NN of_IN any_DT
        antibiotic_NN once_RB you_PRP start_VBP to_TO use_VB it_PRP ._. That_DT cannot_NN be_VB argued_VBN ._.”
      
    
  
